Hari Jayaram. Defining and characterizing the components of a CRISPR-Cas9 genomic medicine. Presented at the CRISPR 2017 International Conference, Big Sky, Montana, June 8 – 10, 2017.

Dec

12

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec

9

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Nov

6

Editas Medicine to Participate in Upcoming Investor Conferences